MOTS-c Geriatric (65+) Caregiver Administration Guidance

What Is MOTS-c and Why Does It Matter for Older Adults?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded entirely within the mitochondrial genome, not the nuclear genome. Serum levels fall measurably with age in humans, and that age-related decline tracks closely with reduced insulin sensitivity and diminished skeletal-muscle function. For adults over 65, this matters because both of those downstream effects compound existing sarcopenia and metabolic risk.

The Foundational Science

Lee and colleagues published the first characterization of MOTS-c in 2015 in Cell Metabolism, showing that the peptide activates the AMPK pathway in skeletal muscle, improves glucose uptake independently of insulin, and reduces diet-induced obesity in mice (1). The authors demonstrated that exogenous MOTS-c administration restored exercise capacity and insulin sensitivity in aged mice, a finding that seeded the current wave of human trials.

A 2023 analysis in Aging by Kim et al. Quantified circulating MOTS-c in 141 healthy volunteers and found plasma concentrations in adults over 65 averaged roughly 40% lower than in adults aged 20 to 35 (2). That magnitude of decline is comparable to the testosterone drop seen across the same age span, which gives clinical context for why researchers are testing exogenous repletion.

Relevance to Sarcopenia and Metabolic Syndrome

Sarcopenia affects an estimated 10% to 27% of community-dwelling adults aged 65 and older globally, depending on the diagnostic criteria applied, according to a 2022 systematic review and meta-analysis (N = 58,404) in Age and Ageing (3). MOTS-c's mechanism sits upstream of mTOR and directly engages mitochondrial biogenesis, which is precisely the pathway most compromised in age-related muscle loss. Caregivers should understand this mechanistic context because it explains why consistent, on-schedule dosing is more important than, say, a missed antihistamine.

Regulatory Status and Caregiver Legal Obligations

MOTS-c carries no FDA-approved indication as of July 2025. Preparations dispensed to patients come from compounding pharmacies operating under Section 503A (patient-specific) or 503B (outsourcing facility) of the Federal Food, Drug, and Cosmetic Act, which the FDA oversees through its compounding guidance documents (4).

What "Investigational" Means at Bedside

A drug being investigational does not mean unmonitored. Prescribing providers assume responsibility for informed consent, baseline labs, and adverse-event reporting. Caregivers, in turn, are an extension of that safety system. The FDA's MedWatch program accepts reports from caregivers and family members, not only licensed clinicians (5).

Liability and Documentation

Caregivers administering injectable medications in home settings should maintain a written log for every injection: date, time, dose drawn (in mg and mL), injection site used, lot number from the vial, and any immediate reactions. This log is the first document a provider or pharmacist will request if an adverse event occurs.

Caregiver Prerequisites Before the First Injection

Not every caregiver is ready to give subcutaneous injections on day one. The patient's prescribing provider should confirm the following before handing over a vial.

Skills Assessment

The caregiver should be able to:

• Draw up a precise volume (within 0.05 mL) from a multi-dose vial using a 1 mL insulin syringe
• Identify and avoid lipohypertrophy nodules on the abdomen, thighs, and deltoid areas
• Perform a 30-second hand-wash and don clean (not necessarily sterile) gloves
• Recognize a contaminated needle and discard it without recapping

Insulin self-injection training programs, widely available through the American Diabetes Association (6), use the same syringe type and injection-site map that applies to MOTS-c administration. Caregivers with no prior injection experience should complete at least one supervised practice session with a nurse or pharmacist before solo administration.

Cognitive and Physical Readiness of the Caregiver

Caregivers who are themselves elderly or who have arthritis affecting hand strength may have difficulty with fine-motor syringe tasks. Auto-injector devices exist for some peptide formulations; ask the compounding pharmacy whether a device version is available. If the caregiver's vision is impaired, a magnifying syringe reader or pre-filled syringe service through the compounding pharmacy reduces drawing errors.

Reconstitution: Step-by-Step Protocol

Lyophilized MOTS-c arrives as a white or off-white powder in a sealed glass vial, typically 5 mg or 10 mg per vial. Reconstitution uses bacteriostatic water for injection (BAW).

Materials Checklist

Before starting, gather:

1. MOTS-c lyophilized vial (verify lot number and expiry)
2. Bacteriostatic water for injection, 10 mL multi-dose vial
3. Two alcohol prep pads (70% isopropyl)
4. One 3 mL syringe with 23-gauge draw needle (for reconstitution)
5. One 1 mL insulin syringe with 29 to 31 gauge, 4 to 6 mm needle (for injection)
6. Sharps disposal container
7. Clean, flat surface lined with a fresh paper towel

Reconstitution Steps

1. Wash hands for 30 seconds. Put on clean gloves.
2. Wipe the rubber stopper of both vials with a fresh alcohol pad. Allow 10 seconds to air-dry. Do not blow on the stopper.
3. Draw the appropriate volume of BAW into the 3 mL syringe. For a 10 mg vial, 2 mL of BAW yields a 5 mg/mL concentration. For a 5 mg vial, 1 mL of BAW yields a 5 mg/mL concentration. Confirm the target concentration with the prescribing provider before the first reconstitution.
4. Insert the needle into the MOTS-c vial at a 45-degree angle. Aim the BAW stream at the glass wall, not directly at the powder, to avoid foaming. Inject slowly.
5. Gently roll the vial between palms for 15 to 20 seconds. Never shake. Shaking denatures peptide bonds.
6. The solution should be clear and colorless. Discard if particulate matter or discoloration is visible.
7. Label the vial with the reconstitution date and time. Refrigerate immediately. Use within 28 days of reconstitution per standard bacteriostatic-water stability guidance (7).

Injection Technique for Older Adults

Subcutaneous tissue thins with age. A 2019 ultrasound study published in Diabetes, Obesity and Metabolism (N = 388) found that mean subcutaneous fat depth at the abdomen decreased by approximately 1.8 mm per decade after age 50, with the sharpest decline occurring after age 70 (8). Thinner subcutaneous tissue raises the risk of inadvertent intramuscular injection, which is more painful, increases bruising, and may alter absorption kinetics.

Needle Selection

For patients aged 65 and older, a 4 mm needle length at a 90-degree angle is generally safe for abdominal injections unless body mass index is below 22 kg/m², in which case a 45-degree angle with a 4 mm needle or a 90-degree angle at a pinch reduces intramuscular risk. The American Diabetes Association's 2023 consensus on insulin delivery technology (9) recommends needle lengths of 4 to 6 mm for most adults, guidance that transfers directly to subcutaneous peptide injections.

Site Rotation for Geriatric Patients

Use a systematic rotation map. Divide the abdomen into four quadrants (upper-right, upper-left, lower-right, lower-left). Rotate clockwise, moving at least 2 cm from the previous site within each quadrant. The outer thighs and dorsal deltoid area serve as secondary sites. Avoid:

• The 2 cm radius around the navel
• Skin folds with visible telangiectasias or atrophic scarring
• Any site with lipohypertrophy (feels rubbery or thickened on palpation)
• Bruised or broken skin

For patients with significant abdominal adiposity (common in metabolic syndrome, which co-exists with low MOTS-c levels), the outer thigh may paradoxically offer better subcutaneous depth. Check with the provider if unsure.

Injection Steps

1. Remove the reconstituted vial from the refrigerator 10 to 15 minutes before injection to bring it to room temperature. Cold solution increases injection-site stinging.
2. Draw the prescribed volume into the 1 mL insulin syringe, watching for air bubbles. Flick the syringe and expel bubbles before withdrawing the needle from the vial.
3. Confirm the drawn volume against the dose record. A verbal double-check with the patient ("I have 0.2 mL drawn, which is 1 mg at our concentration") is a simple error-reduction step.
4. Clean the injection site with an alcohol pad. Allow 10 seconds to air-dry completely. Wet alcohol is painful and may carry surface bacteria into the tissue.
5. Pinch a 2 cm fold of skin if the patient is lean. Insert the needle at the planned angle with a smooth, single motion.
6. Inject slowly, over 5 to 10 seconds.
7. Withdraw the needle at the same angle it entered. Apply gentle pressure with a dry cotton ball for 10 seconds. Do not rub; rubbing accelerates local dispersion and may increase bruising.
8. Dispose of the entire syringe, uncapped, in the sharps container immediately.

Dosing Schedules and Age-Related Pharmacokinetic Considerations

No pharmacokinetic study specific to adults over 65 has yet been published in peer-reviewed literature for MOTS-c as of the date of this article. What exists are:

• The first-in-human Phase I trial (NCT02577263) which enrolled adults aged 25 to 55 and tested single ascending doses up to 0.6 mg/kg without dose-limiting toxicity (10)
• Mouse aging studies showing that aged animals required dose-adjusted protocols to achieve the same plasma AUC as young animals, suggesting possible age-related clearance differences

Because of this evidence gap, HealthRX's clinical team applies the following pragmatic geriatric dosing framework for MOTS-c, pending peer-reviewed human PK data in older cohorts:

Geriatric MOTS-c Dosing Framework (HealthRX Internal, July 2025)

| Phase | Dose | Frequency | Duration | |---|---|---|---| | Initiation | 5 mg | 3x/week (Mon, Wed, Fri) | Weeks 1 to 4 | | Maintenance | 5 to 10 mg | 3 to 5x/week | Weeks 5 to 12 | | Re-evaluation | Per provider assessment | Per provider assessment | Week 13+ |

Caregivers should record the exact day and time of each injection in the dose log. If a dose is missed by more than 24 hours, skip it and resume the next scheduled injection. Never double-dose to compensate.

Timing Considerations

MOTS-c's exercise-mimetic AMPK activation raises the question of whether injection timing relative to meals or physical activity matters. A 2021 paper in Nature Aging by Reynolds et al. Demonstrated in older adults (mean age 72) that mitochondrial AMPK signaling is most responsive in the 2-hour window after a mixed meal (11). Administering MOTS-c 30 to 60 minutes before the patient's main meal of the day may align with this biological window, though direct evidence for MOTS-c specifically is still pending.

Safety Monitoring for Geriatric Patients

Older adults carry higher baseline risks for the adverse effects most plausible with MOTS-c: hypoglycemia (due to AMPK-mediated glucose uptake), blood-pressure variability, and injection-site complications.

Blood Glucose Monitoring

Patients on sulfonylureas, insulin, or other glucose-lowering agents face additive hypoglycemia risk. The ADA's 2024 Standards of Care recommend a glycemic target of HbA1c <7.5% for most older adults on complex regimens, with less stringent targets for those with functional limitations (12). Any caregiver co-managing a patient with diabetes should check fingerstick glucose before each MOTS-c injection for at least the first four weeks.

Values below 70 mg/dL before injection warrant a 15-gram fast-acting carbohydrate correction (e.g., 4 glucose tablets) and a 15-minute recheck before proceeding. Values below 54 mg/dL require holding the injection and calling the provider.

Blood Pressure and Heart Rate

Systolic blood pressure below 100 mmHg before injection should prompt caregiver contact with the provider before proceeding. MOTS-c has not shown clinically significant vasodepressor effects in published data, but older adults with polypharmacy (particularly those on ACE inhibitors, ARBs, or alpha-blockers) are more sensitive to additive drops in blood pressure following any peptide injection that influences vascular tone.

Injection-Site Inspection

At each visit, before injecting, palpate the planned site and visually inspect all prior sites. Look for:

• Induration (hardened nodule, >1 cm diameter): skip that site for at least 2 weeks
• Erythema spreading beyond 2 cm from the prior puncture: photograph, document, and contact the provider within 24 hours
• Ecchymosis: acceptable if <2 cm; document size and monitor at next visit

Systemic Red Flags Requiring Immediate Action

Call 911 immediately and do not administer the injection if the patient shows:

• Urticaria, throat tightening, or stridor (anaphylaxis protocol)
• Chest pain or new-onset dyspnea
• Syncope or loss of consciousness
• Acute confusion markedly different from baseline

Storage, Handling, and Supply Chain for Geriatric Households

Multi-drug households are the norm for adults over 65. The CDC reports that 42% of adults aged 65 and older take five or more prescription medications (13). MOTS-c vials must be physically segregated from oral medications to prevent dosing errors, and caregivers managing multiple injectables (e.g., insulin, GLP-1 agonists) should use color-coded labels.

Temperature Excursion Protocol

If power is lost and refrigerator temperature rises above 8°C, the lyophilized (un-reconstituted) vial remains stable for up to 7 days at room temperature below 25°C per peptide stability consensus data published by the U.S. Pharmacopeia (14). Reconstituted solution should be discarded after any temperature excursion above 25°C lasting more than 4 hours. When in doubt, discard. The cost of one vial is trivial compared to the risk of administering a degraded peptide.

Travel Considerations

For outings lasting more than 2 hours, use an insulated medication travel case with a gel ice pack (not direct-contact dry ice, which freezes the solution). Airline travel: MOTS-c vials qualify as a liquid medication and are exempt from the 3.4 oz rule under TSA guidelines when accompanied by a prescription label (15).

Communication Between Caregiver and Clinical Team

A caregiver's observations are primary clinical data. Providers often see geriatric patients quarterly or less frequently; the caregiver is the continuous observer.

What to Log at Every Injection Visit

• Date, time, exact dose and concentration
• Injection site used (use a body diagram if available)
• Lot number and expiry of the vial
• Pre-injection fingerstick glucose (if patient has diabetes or metabolic syndrome)
• Pre-injection blood pressure (if patient is hypertensive or on antihypertensives)
• Any patient-reported symptoms in the prior 24 hours: fatigue, dizziness, injection-site discomfort, GI symptoms, mood changes
• Caregiver observations: skin color, gait, affect

This log should be shared with the prescribing provider at every appointment. A 2022 study in JAMA Internal Medicine (N = 4,210) found that caregiver-reported symptom logs reduced medication-related hospitalizations in older adults by 18% compared to standard care (16).

Escalation Thresholds

Contact the provider within 24 hours (non-emergency) for:

• Any new injection-site erythema or induration
• Patient-reported new-onset fatigue that began within 48 hours of an injection
• Two consecutive fingerstick readings below 70 mg/dL before injections
• Unexplained weight loss of more than 2 kg in 2 weeks (may signal excessive AMPK activation in a cachectic patient)

Contact the provider within 1 hour (urgent, not emergency) for:

• Systolic BP below 90 mmHg on two readings 5 minutes apart
• Patient unable to ambulate safely on a day when they were ambulatory at the prior visit
• Any new neurological symptom: slurred speech, unilateral weakness, severe headache

Special Populations Within the 65-Plus Age Group

Patients with Frailty (Fried Criteria Score 3 to 5)

Frail patients may have subcutaneous tissue depths that make even a 4 mm needle problematic at 90 degrees. A 2-to-3 mm skin lift (tent technique) with a 4 mm needle at 45 degrees is the safest approach. Frailty also increases fall risk from any intervention that lowers blood pressure or blood glucose transiently. Ensure the patient is seated or supine during and for 10 minutes after the injection.

Patients with Cognitive Impairment

Patients with mild-to-moderate dementia may not reliably report injection-site pain or systemic symptoms. Caregivers should perform a full skin inspection of all rotation sites at each visit, not just the planned site. The patient should be calmly informed of what is about to happen at each step, even if comprehension is uncertain. Behavioral distress during injection may indicate an inadvertent intramuscular placement at prior sessions; review site and technique with the clinical team.

Patients on Anticoagulants

Warfarin, apixaban, rivaroxaban, and dabigatran all increase bruising risk from subcutaneous injections. This is not a contraindication, but it does require:

• 4 mm needle to minimize trauma
• 30-second firm pressure post-injection (not 10 seconds)
• Documentation of bruise diameter and resolution time at every visit
• Notification to the provider if a single bruise exceeds 5 cm or fails to resolve within 10 days